The proposed bill aims to enhance patient access to discounted medications and health care services in Washington by safeguarding the integrity of the federal 340B drug pricing program. It prohibits drug manufacturers, distributors, and third-party logistics providers from denying or restricting the acquisition and delivery of 340B drugs to covered entities and their contracted pharmacies. The bill also establishes that these entities cannot be required to submit claims or data as a condition for receiving 340B drugs unless mandated by federal law. Additionally, it allows covered entities to file civil actions against violators and empowers the attorney general to enforce the provisions of the bill, which includes penalties for non-compliance.

Furthermore, the bill mandates covered entities to report specific data regarding their participation in the 340B program annually, including acquisition costs, payments received, and how savings are utilized for community benefits. The Department of Health is tasked with compiling this data and reporting it to the legislature, while ensuring confidentiality of the information, except for manufacturer data related to 340B discounts, which may be publicly released. The bill also amends existing law to include provisions for the reporting of 340B program data and emphasizes the importance of the program in supporting low-income and uninsured populations in accessing necessary medications and health services.

Statutes affected:
Substitute bill: 43.71C.100